Eagle Pharmaceuticals (EGRX) Misses Q4 EPS Views

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Eagle Pharmaceuticals (EGRX) Misses Q4 EPS Views

Mizuho Securities Remains Bullish on Eagle Pharmaceuticals (EGRX) Despite Weak 4Q; Investors Focus on Bendeka Opportunity

February 26, 2016 7:04 AM EST

Mizuho Securities maintained a Buy rating on Eagle Pharmaceuticals (NASDAQ: EGRX), and cut the price target to $81.00 (from $112.00), following the company's 4Q earnings report. EGRX reported 4Q revenues of $18.2M and EPS of $0.07, missing the consensus estimates of $20.8M and $0.30. The most... More